SCYX · Scynexis Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $334.0K | $1.36M | $257.0K | - | $660.0K | $736.0K | $1.37M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $12.35M | - | $5.45M | $7.14M | $5.14M | - | $8.07M | $6.81M | $7.21M | - |
| SG&A | $4.59M | - | $3.29M | $3.78M | $3.73M | - | $2.91M | $3.17M | $3.67M | - |
| Total Operating Expenses | $16.94M | - | $8.74M | $10.93M | $8.87M | - | $10.98M | $9.97M | $10.88M | - |
| D&A | - | - | - | - | - | - | - | - | $0 | - |
| Operating Income | ($16.94M) | - | ($8.40M) | ($9.56M) | ($8.61M) | - | ($10.32M) | ($9.24M) | ($9.51M) | - |
| Interest Expense | $0 | - | $0 | $197.0K | $205.0K | - | $213.0K | $197.0K | $205.0K | - |
| Income Tax | - | - | $0 | $0 | $0 | - | ($395.0K) | $0 | $531.0K | - |
| Net Income | ($21.30M) | - | ($8.59M) | ($6.88M) | ($5.39M) | - | ($2.81M) | ($14.46M) | $411.0K | - |
| EPS - Basic | ($3.36) | - | ($1.36) | ($1.12) | ($0.88) | - | ($0.48) | ($2.40) | $0.08 | - |
| EPS - Diluted | ($3.36) | - | ($1.36) | ($1.12) | ($0.88) | - | ($0.48) | ($2.40) | $0.08 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $36.67M | $21.26M | $14.80M | $11.02M | $6.94M | $16.05M | $28.73M | $25.99M | $35.48M | $34.05M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | $0 |
| Inventory | - | - | - | - | - | - | - | - | - | $0 |
| Accounts Payable | $5.63M | $2.23M | $3.47M | $6.17M | $4.26M | $4.57M | $4.96M | $5.35M | $8.92M | $7.15M |
| Current Assets | $62.69M | $40.37M | $48.69M | $56.50M | $52.22M | $72.18M | $80.46M | $94.58M | $101.67M | $102.12M |
| Total Assets | $77.63M | $59.03M | $51.07M | $60.69M | $67.92M | $90.64M | $99.04M | $107.81M | $118.25M | $128.41M |
| Current Liabilities | $15.90M | $5.73M | $8.47M | $10.86M | $8.96M | $24.10M | $25.72M | $25.23M | $27.35M | $16.30M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $36.32M | $9.65M | $14.64M | $16.23M | $17.38M | $35.57M | $40.51M | $47.40M | $44.15M | $55.45M |
| Stockholders' Equity | $41.31M | $49.38M | $36.43M | $44.47M | $50.53M | $55.08M | $58.53M | $60.41M | $74.11M | $72.96M |
| Retained Earnings | ($406.44M) | ($385.14M) | ($397.40M) | ($388.81M) | ($381.93M) | ($376.54M) | ($372.10M) | ($369.29M) | ($354.84M) | ($355.25M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.10M) | - | - | - | ($7.46M) | - | - | - | ($4.01M) | - |
| Investing Cash Flow | ($525.0K) | - | - | - | $12.44M | - | - | - | $5.45M | - |
| Financing Cash Flow | $24.04M | - | - | - | ($14.08M) | - | - | - | ($15.0K) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -2516.5% | -701.0% | -3350.2% | - | -1563.6% | -1255.0% | -692.5% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -692.5% | - |
| Net margin | - | - | -2572.2% | -504.8% | -2097.7% | - | -425.5% | -1964.4% | 29.9% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 1632.3% | 523.5% | 2000.4% | - | 1223.2% | 924.9% | 525.3% | - |
| SG&A / Revenue | - | - | 984.1% | 277.4% | 1449.8% | - | 440.5% | 430.2% | 267.2% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | 56.4% | - |
| Return on assets | -27.4% | - | -16.8% | -11.3% | -7.9% | - | -2.8% | -13.4% | 0.3% | - |
| Return on equity | -51.6% | - | -23.6% | -15.5% | -10.7% | - | -4.8% | -23.9% | 0.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.94 | 7.04 | 5.75 | 5.20 | 5.83 | 3.00 | 3.13 | 3.75 | 3.72 | 6.26 |
| Quick ratio | 3.94 | 7.04 | 5.75 | 5.20 | 5.83 | 3.00 | 3.13 | 3.75 | 3.72 | 6.26 |
| Cash ratio | 2.31 | 3.71 | 1.75 | 1.01 | 0.78 | 0.67 | 1.12 | 1.03 | 1.30 | 2.09 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | -48.5x | -42.0x | - | -48.5x | -46.9x | -46.4x | - |
| Equity multiplier | 1.88 | 1.20 | 1.40 | 1.36 | 1.34 | 1.65 | 1.69 | 1.78 | 1.60 | 1.76 |
| Liabilities / Assets | 0.47 | 0.16 | 0.29 | 0.27 | 0.26 | 0.39 | 0.41 | 0.44 | 0.37 | 0.43 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.01 | 0.02 | 0.00 | - | 0.01 | 0.01 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | 147.0x | - |
| P / B | 1.1x | - | 1.1x | 0.8x | 0.9x | - | 1.2x | 12.8x | 7.7x | - |
| P / S | - | - | 115.0x | 24.6x | 183.1x | - | 109.8x | 1054.6x | 416.0x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | - | -49.4% | 85.3% | -81.3% | - | -62.5% | -99.4% | 21.5% | - |
| Revenue CAGR (3y) | - | - | -40.1% | 1.0% | -27.9% | - | 8.6% | - | -51.5% | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | 66.8% | 84.6% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -96.7% | - | 18.6% | -3.5% | 9.4% | - | -2.2% | - | 11.0% | - |
| Net income growth (YoY) | -295.1% | - | -205.9% | 52.4% | - | - | -59.8% | - | - | - |
| EPS growth (YoY) | -281.8% | - | -183.3% | 53.3% | - | - | -1100.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -18.3% | -10.4% | -37.8% | -26.4% | -31.8% | -24.5% | -36.4% | -35.1% | - | 2156.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$20.60M totalLicense And Service$19.16M · 93.0%
Product$1.44M · 7.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing SCYNEXIS INC against the 5 most active filers in the same SIC group.